Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302249 · ClinicalTrials.gov registry record · Phase 2
AR-12286 in Combination With Latanoprost
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT01302249: Completed Phase 2 study, sponsored by Aerie Pharmaceuticals.
NCT01302249 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 66 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01302249, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).
Primary Outcome
The primary efficacy endpoint will be the mean IOP across subjects within treatment group at each study visit at each post-treatment timepoint.
Interventions
- DRUG Latanoprost 0.005%
- DRUG AR-12286 Ophthalmic Solution 0.5%
- DRUG Timolol maleate ophthalmic solution 0.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT01302249 record still lists
NCT01302249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 3 interventions - of which Latanoprost 0.005% is the first listed.
NCT01302249 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01302249 about?
NCT01302249 is a clinical study titled "AR-12286 in Combination With Latanoprost". This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).
What is the current status of trial NCT01302249?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2011-02. Estimated completion is 2011-12.
What interventions are being tested in trial NCT01302249?
The interventions under investigation include: Latanoprost 0.005% (DRUG), AR-12286 Ophthalmic Solution 0.5% (DRUG), Timolol maleate ophthalmic solution 0.5% (DRUG).
Who is sponsoring clinical trial NCT01302249?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01302249's enrollment target sits among peer trials
66 975th of 2000 higher than 1,014 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia